Mastrangelo R, Troncone L, Lasorella A, Riccardi R, Montemaggi P, Rufini V
Department of Pediatrics, Catholic University of Rome, Italy.
Am J Pediatr Hematol Oncol. 1989 Spring;11(1):28-31. doi: 10.1097/00043426-198921000-00007.
Radioactive metaiodobenzylguanidine (131I-MIBG) is taken up specifically by neuroblastoma cells and appears to represent a new treatment modality in patients with advanced neuroblastoma. Taking into account the fact that all patients so far treated were heavily pretreated and resistant to chemotherapy, the results obtained appear encouraging. In order to explore further the potential role of this new drug in untreated patients, we treated with 131I-MIBG a child with stage III neuroblastoma at diagnosis. We observed the complete disappearance of a large abdominal tumor mass after a relatively low dosage of 131I-MIBG, with minimal hematologic toxicity. No further treatment was given and, at present, the patient is alive with no evidence of disease 18 months from diagnosis. This child represents, to our knowledge, the only case of neuroblastoma thus far treated at diagnosis and the excellent response obtained suggests the need for further investigations of this therapy in untreated patients.
放射性间碘苄胍（131I-MIBG）能被神经母细胞瘤细胞特异性摄取，似乎代表了晚期神经母细胞瘤患者的一种新的治疗方式。考虑到迄今为止接受治疗的所有患者均经过大量前期治疗且对化疗耐药，所获得的结果看起来令人鼓舞。为了进一步探究这种新药在未经治疗患者中的潜在作用，我们在诊断时用131I-MIBG治疗了一名III期神经母细胞瘤患儿。我们观察到在给予相对低剂量的131I-MIBG后，一个巨大的腹部肿瘤肿块完全消失，血液学毒性极小。未给予进一步治疗，目前，该患者自诊断后18个月仍存活，无疾病证据。据我们所知，这名儿童是迄今为止在诊断时接受治疗的唯一一例神经母细胞瘤患者，所获得的良好反应表明有必要在未经治疗的患者中对这种疗法进行进一步研究。
